enGene Therapeutics Inc. (ENGN)

NASDAQ: ENGN · Real-Time Price · USD

1.740

-0.010 (-0.57%)

At close: Jun 17, 2026, 4:00 PM EDT

1.755

+0.015 (0.86%)

After-hours: Jun 17, 2026, 6:57 PM EDT

enGene Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022
Net Income	-126.85	-117.3	-55.14	-99.92	-24.46
Depreciation & Amortization	0.67	0.51	0.32	0.18	0.24
Stock-Based Compensation	12.14	9.65	5.32	3.45	0.12
Other Adjustments	-0.13	-1.88	0.8	72.07	4.34
Changes in Accounts Payable	-0.11	4.94	0.47	0.37	-0.2
Changes in Accrued Expenses	4.99	3.13	5.23	0.87	2.34
Changes in Other Operating Activities	-0.83	1.67	-5.6	-1.76	0.03
Operating Cash Flow	-110	-99.24	-48.28	-24.74	-17.59
Capital Expenditures	-1.39	-1.49	-0.93	-0.32	-0.15
Purchases of Investments	-271.82	-160.84	-125.03	-	-
Proceeds from Sale of Investments	212.43	137.19	-	-	-
Investing Cash Flow	-60.78	-25.14	-125.95	-0.32	-0.15
Long-Term Debt Issued	25	-	22.5	38	29.4
Long-Term Debt Repaid	-23.75	-0.7	-9.45	-4.73	-1.01
Net Long-Term Debt Issued (Repaid)	1.25	-0.7	13.06	33.27	28.39
Issuance of Common Stock	151.8	2.22	266.25	64.3	0.01
Net Common Stock Issued (Repurchased)	151.8	2.22	266.25	64.3	0.01
Other Financing Activities	-9.99	-	-13.58	-11.42	-0.44
Financing Cash Flow	143.06	1.52	265.72	86.15	27.97
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0	0	0	-	-0.81
Net Cash Flow	-27.72	-122.85	91.48	61.09	9.42
Free Cash Flow	-111.39	-100.72	-49.21	-25.06	-17.75
Free Cash Flow Per Share	-1.86	-1.97	-1.30	-36.18	-27.09
Levered Free Cash Flow	-122.27	-109.24	-42.59	-72.13	1.63
Unlevered Free Cash Flow	-128.98	-114.4	-62.78	-26.72	-17.19

SEC Filings: 10-K · 10-Q